OPTIMIZING THE ASSESSMENT OF DISEASE ACTIVITY DURING TREATMENT WITH ANTI-RHEUMATOID DRUGS

Publisher Website
Google Scholar
Abstract
Clinical trials in RA usually involve the use of several laboratory assessments of disease activity. Their use is not universal and the relative value of many novel assessments has not been determined in relation to existing clinical and laboratory methods. This study attempts to investigate the value of established and novel assessments of disease activity during treatment with accepted DMARDs. Over a 48-week study period, changes in cytidine deaminase (CD), β2-microglobulin, α1-acid glycoprotein (α1-AGP) serum antibodies to Clostridium perfringens α-toxin, pre-albumin and caeruloplasmin were compared to a group of established clinical and laboratory assessments including plasma viscosity, CRP haemoglobin and platelet count during treatment with the established second-line drugs, D-penicillamine (n=20), sulphasalazine (n=17), gold (n=12) and hydroxychloroquine (n=18). Overall, the assessments showing the greatest degree of change were plasma viscosity, articular index, summated change score, platelet count, CD, white cell count, α1AGP, CRP and pain score. The assessments showing the greatest degree of change were not homologous between the treatment groups and no single assessment was outstanding for a particular drug treatment.

This publication has 0 references indexed in Scilit: